Table 3. Prevalence of fetal and maternal outcomes in the studied population according to labetalol and methyldopa when prescribed alone.
| Variables | Labetalol n (%) |
Methyldopa n (%) |
Total n (%) |
p-value |
|---|---|---|---|---|
| Risk factors | ||||
| Age, mean ± SD, years | 31.9 ± 5.3 | 33.4 ± 4.8 | 32.4 ± 5.2 | 0.150 |
| Associated DM | 22 (31.0%) | 19 (51.4) | 41 (38.0) | 0.038 |
| Fetal outcomes | ||||
| Low birth weight | 19 (28.8) | 8 (19.5) | 27 (25.2) | 0.283 |
| Preterm delivery | 7 (10.6) | 8 (19.5) | 15 (13.9) | 0.216 |
| IUGR | 11 (16.7) | 5 (12.2) | 16 (15.0) | 0.528 |
| SGA | 5 (7.6) | 2 (4.9) | 7 (6.5) | 0.583 |
| Hypoglycemia | 5 (7.6) | 1 (2.4) | 6 (5.6) | 0.262 |
| Congenital defects | 1 (1.5) | 2 (4.9) | 3 (2.8) | 0.306 |
| Seizures | 0 (0.0) | 1 (2.4) | 1 (0.9) | 0.202 |
| RDS | 6 (9.1) | 3 (7.3) | 9 (8.4) | 0.748 |
| Fetal bradycardia | 8 (12.1) | 1 (2.4) | 9 (8.4) | 0.079 |
| Perinatal depression | 3 (4.5) | 0 (0.0) | 3 (2.8) | 0.166 |
| PPROM | 2 (3.0) | 0 (0.0) | 2 (1.9) | 0.261 |
| Absent end diastolic flow | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
| NNCU admission | 21 (31.8) | 5 (12.2) | 26 (24.3) | 0.021 |
| Maternal outcomes | ||||
| Preeclampsia | 33 (50.0) | 7 (16.7) | 40 (37.0) | < 0.001 |
| Eclampsia | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
| Postpartum hemorrhage | 10 (15.2) | 5 (11.9) | 15 (13.9) | 0.634 |
| Antepartum bleeding | 7 (10.6) | 5 (11.9) | 12 (11.1) | 0.834 |
| Placental abruption | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
| HDU admission | 16 (24.2) | 5 (11.9) | 21 (19.4) | 0.114 |
SD: standard deviation; DM: diabetes mellitus; IUGR: intrauterine growth restriction; SGA: small for gestational age; RDS: respiratory distress syndrome; PPROM: preterm premature rapture of membranes. NNCU: neonatal care unit; HDU: high dependency unit.